Promoting Undetectable Equals Untransmittable in Sub-Saharan Africa: Implication for Clinical Practice and ART Adherence
Abstract
:1. Introduction
2. U = U: The Concept, the Science
2.1. Low Viral Load and Transmissibility: The Evidence Supporting U = U
2.2. Transcriptional Silencing
2.3. Clinical Significance of ART Induced Transcriptional Silencing, U = U
3. HIV Clinical Practice in Sub-Saharan Africa and Its Challenges
4. Factors Affecting Adherence to ART in Sub-Saharan Africa
5. Promoting U = U in Sub-Saharan Africa and the Consequences for Controlling HIV
- Clinicians and healthcare providers should discuss U = U with PLWHIV
- Translating of U = U campaign into local dialect as SSA countries have several languages
- Health facilities in SSA countries should have posters (pictorial and words) at HIV clinics to constantly remind patients of U = U
- Community engagement promotion strategies such as display of U = U campaign banners and posters in community facilities that people often visit
- Local and opinion leaders as champions and ambassadors of U = U
- Radio and television adverts
- Social media use
Barriers to U = U | Possible Interventions |
|
|
6. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Fischl, M.A.; Richman, D.D.; Grieco, M.H.; Gottlieb, M.S.; Volberding, P.A.; Laskin, O.L.; Leedom, J.M.; Groopman, J.E.; Mildvan, D.; Schooley, R.T.; et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N. Engl. J. Med. 1987, 317, 185–191. [Google Scholar] [CrossRef] [PubMed]
- Fischl, M.A.; Richman, D.D.; Hansen, N.; Collier, A.C.; Carey, J.T.; Para, M.F.; Hardy, W.D.; Dolin, R.; Powderly, W.G.; Allan, J.D.; et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann. Intern. Med. 1990, 112, 727–737. [Google Scholar] [CrossRef] [PubMed]
- Mulder, J.W.; Cooper, D.A.; Mathiesen, L.; Sandstrom, E.; Clumeck, N.; Gatell, J.M.; French, M.; Donovan, B.; Gray, F.; Yeo, J.M.; et al. Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: A randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017). AIDS 1994, 8, 313–321. [Google Scholar] [CrossRef] [PubMed]
- Hammer, S.M.; Katzenstein, D.A.; Hughes, M.D.; Gundacker, H.; Schooley, R.T.; Haubrich, R.H.; Henry, W.K.; Lederman, M.M.; Phair, J.P.; Niu, M.; et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N. Engl. J. Med. 1996, 335, 1081–1090. [Google Scholar] [CrossRef] [PubMed]
- Darbyshire, J.H. Delta: A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996, 348, 283–291. [Google Scholar] [CrossRef]
- Garcia, F.; Romeu, J.; Grau, I.; Sambeat, M.A.; Dalmau, D.; Knobel, H.; Gomez-Sirvent, J.L.; Arrizabalaga, J.; Cruceta, A.; Clotet, B.G.; et al. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: The Spanish Earth-1 study. AIDS 1999, 13, 2377–2388. [Google Scholar] [CrossRef] [Green Version]
- Hogg, R.S.; Rhone, S.A.; Yip, B.; Sherlock, C.; Conway, B.; Schechter, M.T.; O’Shaughnessy, M.V.; Montaner, J.S. Antiviral effect of double and triple drug combinations amongst HIV-infected adults: Lessons from the implementation of viral load-driven antiretroviral therapy. AIDS 1998, 12, 279–284. [Google Scholar] [CrossRef]
- Attia, S.; Egger, M.; Muller, M.; Zwahlen, M.; Low, N. Sexual transmission of HIV according to viral load and antiretroviral therapy: Systematic review and meta-analysis. AIDS 2009, 23, 1397–1404. [Google Scholar] [CrossRef]
- Quinn, T.C.; Wawer, M.J.; Sewankambo, N.; Serwadda, D.; Li, C.; Wabwire-Mangen, F.; Meehan, M.O.; Lutalo, T.; Gray, R.H. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N. Engl. J. Med. 2000, 342, 921–929. [Google Scholar] [CrossRef]
- Cohen, M.S.; Chen, Y.Q.; McCauley, M.; Gamble, T.; Hosseinipour, M.C.; Kumarasamy, N.; Hakim, J.G.; Kumwenda, J.; Grinsztejn, B.; Pilotto, J.H.S.; et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N. Engl. J. Med. 2016, 375, 830–839. [Google Scholar] [CrossRef]
- WHO. Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants. Available online: https://www.who.int/hiv/pub/mtct/programmatic_update2012/en/ (accessed on 6 August 2020).
- Shapiro, R.L.; Hughes, M.D.; Ogwu, A.; Kitch, D.; Lockman, S.; Moffat, C.; Makhema, J.; Moyo, S.; Thior, I.; McIntosh, K.; et al. Antiretroviral regimens in pregnancy and breast-feeding in botswana. N. Engl. J. Med. 2010, 362, 2282–2294. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cohen, M.S.; Chen, Y.Q.; McCauley, M.; Gamble, T.; Hosseinipour, M.C.; Kumarasamy, N.; Hakim, J.G.; Kumwenda, J.; Grinsztejn, B.; Pilotto, J.H.; et al. Prevention of HIV-1 infection with early antiretroviral therapy. N. Engl. J. Med. 2011, 365, 493–505. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rutherford, G.W.; Anglemyer, A. Early initiation of antiretroviral therapy prevents HIV transmission to seronegative sexual partners. BMJ Evid.-Based Med. 2017, 22, 29. [Google Scholar] [CrossRef] [PubMed]
- Eisinger, R.W.; Dieffenbach, C.W.; Fauci, A.S. HIV viral load and transmissibility of hiv infection: Undetectable equals untransmittable. JAMA 2019, 321, 451–452. [Google Scholar] [CrossRef] [PubMed]
- Rodger, A.J.; Cambiano, V.; Bruun, T.; Vernazza, P.; Collins, S.; van Lunzen, J.; Corbelli, G.M.; Estrada, V.; Geretti, A.M.; Beloukas, A.; et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-Positive partner is using suppressive antiretroviral therapy. JAMA 2016, 316, 171–181. [Google Scholar] [CrossRef]
- Grulich, A.E.; Bavinton, B.R.; Jin, F.; Prestage, G.; Zablotska, I.; Grinsztejn, B.; Phanuphak, N.; Moore, R.; Koelsch, K.K. Opposites attract study group. HIV treatment prevents HIV transmission in male serodiscordant couples in Australia, Thailand and Brazil. In Proceedings of the IAS Conference on HIV Science, Paris, France, 23–26 July 2017. [Google Scholar]
- Yukl, S.A.; Gianella, S.; Sinclair, E.; Epling, L.; Li, Q.; Duan, L.; Choi, A.L.; Girling, V.; Ho, T.; Li, P.; et al. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J. Infect. Dis. 2010, 202, 1553–1561. [Google Scholar] [CrossRef] [Green Version]
- Finzi, D.; Blankson, J.; Siliciano, J.D.; Margolick, J.B.; Chadwick, K.; Pierson, T.; Smith, K.; Lisziewicz, J.; Lori, F.; Flexner, C.; et al. Latent infection of CD4+T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 1999, 5, 512–517. [Google Scholar] [CrossRef]
- Finzi, D.; Hermankova, M.; Pierson, T.; Carruth, L.M.; Buck, C.; Chaisson, R.E.; Quinn, T.C.; Chadwick, K.; Margolick, J.; Brookmeyer, R.; et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278, 1295–1300. [Google Scholar] [CrossRef]
- Cory, T.J.; Schacker, T.W.; Stevenson, M.; Fletcher, C.V. Overcoming pharmacologic sanctuaries. Curr. Opin. HIV AIDS 2013, 8, 190–195. [Google Scholar] [CrossRef] [Green Version]
- Poveda, E.; Tabernilla, A. New insights into HIV-1 persistence in sanctuary sites during antiretroviral therapy. AIDS Rev. 2016, 18, 55. [Google Scholar]
- Darcis, G.; Coombs, R.W.; Van Lint, C. Exploring the anatomical HIV reservoirs: Role of the testicular tissue. AIDS (London England) 2016, 30, 2891–2893. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sengupta, S.; Siliciano, R.F. Targeting the latent reservoir for HIV-1. Immunity 2018, 48, 872–895. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Honeycutt, J.B.; Thayer, W.O.; Baker, C.E.; Ribeiro, R.M.; Lada, S.M.; Cao, Y.; Cleary, R.A.; Hudgens, M.G.; Richman, D.D.; Garcia, J.V. HIV persistence in tissue macrophages of humanized myeloid-only mice during antiretroviral therapy. Nat. Med. 2017, 23, 638–643. [Google Scholar] [CrossRef] [PubMed]
- Ganor, Y.; Real, F.; Sennepin, A.; Dutertre, C.A.; Prevedel, L.; Xu, L.; Tudor, D.; Charmeteau, B.; Couedel-Courteille, A.; Marion, S.; et al. HIV-1 reservoirs in urethral macrophages of patients under suppressive antiretroviral therapy. Nat. Microbiol. 2019, 4, 633–644. [Google Scholar] [CrossRef]
- Clayton, K.L.; Garcia, J.V.; Clements, J.E.; Walker, B.D. HIV infection of macrophages: Implications for pathogenesis and cure. Pathog. Immun. 2017, 2, 179–192. [Google Scholar] [CrossRef] [Green Version]
- Ho, Y.-C.; Shan, L.; Hosmane, N.N.; Wang, J.; Laskey, S.B.; Rosenbloom, D.I.; Lai, J.; Blankson, J.N.; Siliciano, J.D.; Siliciano, R.F. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 2013, 155, 540–551. [Google Scholar] [CrossRef] [Green Version]
- Sedaghat, A.R.; Dinoso, J.B.; Shen, L.; Wilke, C.O.; Siliciano, R.F. Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc. Natl. Acad. Sci. USA 2008, 105, 4832–4837. [Google Scholar] [CrossRef] [Green Version]
- Dornadula, G.; Zhang, H.; Van Uitert, B.; Stern, J.; Livornese, L., Jr.; Ingerman, M.J.; Witek, J.; Kedanis, R.J.; Natkin, J.; DeSimone, J.; et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 1999, 282, 1627–1632. [Google Scholar] [CrossRef] [Green Version]
- Maldarelli, F.; Palmer, S.; King, M.S.; Wiegand, A.; Polis, M.A.; Mican, J.; Kovacs, J.A.; Davey, R.T.; Rock-Kress, D.; Dewar, R.; et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog. 2007, 3, e46. [Google Scholar] [CrossRef] [Green Version]
- Palmer, S.; Maldarelli, F.; Wiegand, A.; Bernstein, B.; Hanna, G.J.; Brun, S.C.; Kempf, D.J.; Mellors, J.W.; Coffin, J.M.; King, M.S. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc. Natl. Acad. Sci. USA 2008, 105, 3879–3884. [Google Scholar] [CrossRef] [Green Version]
- Moon, T.D.; Jequicene, T.; Blevins, M.; Jose, E.; Lankford, J.R.; Wester, C.W.; Fuchs, M.C.; Vermund, S.H. Mobile clinics for antiretroviral therapy in rural Mozambique. Bull. World Health Organ. 2014, 92, 680–684. [Google Scholar] [CrossRef] [PubMed]
- Dube, C.; Nozaki, I.; Hayakawa, T.; Kakimoto, K.; Yamada, N.; Simpungwe, J.B. Expansion of antiretroviral treatment to rural health centre level by a mobile service in Mumbwa district, Zambia. Bull. World Health Organ. 2010, 88, 788–791. [Google Scholar] [CrossRef] [PubMed]
- Lindgren, T.G.; Deutsch, K.; Schell, E.; Bvumbwe, A.; Hart, K.B.; Laviwa, J.; Rankin, S.H. Using mobile clinics to deliver HIV testing and other basic health services in rural Malawi. Rural Remote Health 2011, 11, 1682. [Google Scholar]
- Sagaon-Teyssier, L.; Singh, S.; Dongmo-Nguimfack, B.; Moatti, J.-P. Affordability of adult HIV/AIDS treatment in developing countries: Modelling price determinants for a better insight of the market functioning. J. Int. AIDS Soc. 2016, 19, 20619. [Google Scholar] [CrossRef] [PubMed]
- Kharsany, A.B.M.; Karim, Q.A. HIV infection and AIDS in sub-saharan Africa: Current status, challenges and opportunities. Open AIDS J. 2016, 10, 34–48. [Google Scholar] [CrossRef] [Green Version]
- Joint United Nations Programme on HIV/AIDS (UNAIDS). An Ambitious Treatment Target to Help End the AIDS Epidemic. 2014. Available online: https://www.unaids.org/en/resources/documents/2017/90-90-90 (accessed on 15 March 2020).
- Euvrard, J.; Schulz, T.; Hilderbrand, K.; Bosland, M.; Osler, M.; Boulle, A.; Davies, M.-A. How accurately do routinely reported HIV viral load suppression proportions reflect progress towards the 90-90-90 target in the population on antiretroviral treatment in Khayelitsha, South Africa? S. Afr. Med. J. 2019, 109, 174–177. [Google Scholar] [CrossRef] [Green Version]
- LeMessurier, J.; Traversy, G.; Varsaneux, O.; Weekes, M.; Avey, M.T.; Niragira, O.; Gervais, R.; Guyatt, G.; Rodin, R. Risk of sexual transmission of human immunodeficiency virus with antiretroviral therapy, suppressed viral load and condom use: A systematic review. Cmaj 2018, 190, E1350–E1360. [Google Scholar] [CrossRef] [Green Version]
- Bekker, L.-G.; Alleyne, G.; Baral, S.; Cepeda, J.; Daskalakis, D.; Dowdy, D.; Dybul, M.; Eholie, S.; Esom, K.; Garnett, G.; et al. Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: The International AIDS Society-Lancet Commission. Lancet 2018, 392, 312–358. [Google Scholar] [CrossRef]
- Ehrenkranz, P.D.; Baptiste, S.L.; Bygrave, H.; Ellman, T.; Doi, N.; Grimsrud, A.; Jahn, A.; Kalua, T.; Nyirenda, R.K.; Odo, M.O.; et al. The missed potential of CD4 and viral load testing to improve clinical outcomes for people living with HIV in lower-resource settings. PLoS Med. 2019, 16, e1002820. [Google Scholar] [CrossRef] [Green Version]
- Rice, B.; Boulle, A.; Schwarcz, S.; Shroufi, A.; Rutherford, G.; Hargreaves, J. The continuing value of CD4 cell count monitoring for differential HIV care and surveillance. JMIR Public Health Surveill. 2019, 5, e11136. [Google Scholar] [CrossRef]
- Ford, N.; Calmy, A.; Mills, E.J. The first decade of antiretroviral therapy in Africa. Glob. Health 2011, 7, 33. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wester, C.W.; Bussmann, H.; Koethe, J.; Moffat, C.; Vermund, S.; Essex, M.; Marlink, R.G. Adult combination antiretroviral therapy in sub-Saharan Africa: Lessons from Botswana and future challenges. HIV Ther. 2009, 3, 501–526. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- WHO. Guideline on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV. Available online: www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/ (accessed on 6 August 2020).
- Nsanzimana, S.; Kanters, S.; Mills, E. Towards test and treat strategy for HIV in sub-Saharan Africa. BMJ 2015, 351, h6839. [Google Scholar] [CrossRef] [PubMed]
- Nash, D.; Yotebieng, M.; Sohn, A.H. Treating all people living with HIV in sub-Saharan Africa: A new era calling for new approaches. J. Virus Erad. 2018, 4, 1–4. [Google Scholar] [PubMed]
- Croome, N.; Ahluwalia, M.; Hughes, L.D.; Abas, M. Patient-reported barriers and facilitators to antiretroviral adherence in sub-Saharan Africa. AIDS (London England) 2017, 31, 995–1007. [Google Scholar] [CrossRef] [Green Version]
- Kagee, A.; Remien, R.H.; Berkman, A.; Hoffman, S.; Campos, L.; Swartz, L. Structural barriers to ART adherence in Southern Africa: Challenges and potential ways forward. Glob. Public Health 2011, 6, 83–97. [Google Scholar] [CrossRef] [Green Version]
- Johnston, V.; Fielding, K.; Charalambous, S.; Mampho, M.; Churchyard, G.; Phillips, A.; Grant, A.D. Second-Line antiretroviral therapy in a workplace and community-based treatment programme in South Africa: Determinants of virological outcome. PLoS ONE 2012, 7, e36997. [Google Scholar] [CrossRef]
- Masikini, P.; Mpondo, B.C.T. HIV drug resistance mutations following poor adherence in HIV-infected patient: A case report. Clin. Case Rep. 2015, 3, 353–356. [Google Scholar] [CrossRef]
- Bijker, R.; Jiamsakul, A.; Kityo, C.; Kiertiburanakul, S.; Siwale, M.; Phanuphak, P.; Akanmu, S.; Chaiwarith, R.; Wit, F.W.; Sim, B.L.; et al. Adherence to antiretroviral therapy for HIV in sub-Saharan Africa and Asia: A comparative analysis of two regional cohorts. J. Int. AIDS Soc. 2017, 20, 21218. [Google Scholar] [CrossRef]
- Genberg, B.L.; Lee, Y.; Rogers, W.H.; Wilson, I.B. Four types of barriers to adherence of antiretroviral therapy are associated with decreased adherence over time. AIDS Behav. 2015, 19, 85–92. [Google Scholar] [CrossRef] [Green Version]
- Azia, I.N.; Mukumbang, F.C.; van Wyk, B. Barriers to adherence to antiretroviral treatment in a regional hospital in Vredenburg, Western Cape, South Africa. S. Afr. J. HIV Med. 2016, 17, 476. [Google Scholar] [CrossRef] [PubMed]
- Adeniyi, O.V.; Ajayi, A.I.; Ter Goon, D.; Owolabi, E.O.; Eboh, A.; Lambert, J. Factors affecting adherence to antiretroviral therapy among pregnant women in the Eastern Cape, South Africa. BMC Infect. Dis. 2018, 18, 175. [Google Scholar] [CrossRef] [Green Version]
- Kisenyi, R.N.; Muliira, J.K.; Ayebare, E. Religiosity and adherence to antiretroviral therapy among patients attending a public hospital-based HIV/AIDS clinic in Uganda. J. Relig. Health 2013, 52, 307–317. [Google Scholar] [CrossRef] [PubMed]
- Nachega, J.B.; Hsu, A.J.; Uthman, O.A.; Spinewine, A.; Pham, P.A. Antiretroviral therapy adherence and drug-drug interactions in the aging HIV population. AIDS 2012, 26, S39–S53. [Google Scholar] [CrossRef]
- Salleh, N.A.M.; Richardson, L.; Kerr, T.; Shoveller, J.; Montaner, J.; Kamarulzaman, A.; Milloy, M.J. A longitudinal analysis of daily pill burden and likelihood of optimal adherence to antiretroviral therapy among people living with HIV who use drugs. J. Addict. Med. 2018, 12, 308–314. [Google Scholar] [CrossRef]
- Awortwe, C.; Bouic, P.J.; Masimirembwa, C.M.; Rosenkranz, B. Inhibition of major drug metabolizing cyps by common herbal medicines used by HIV/AIDS patients in Africa-Implications for herb-drug interactions. Drug Metab. Lett. 2014, 7, 83–95. [Google Scholar] [CrossRef] [PubMed]
- Thomford, N.; Awortwe, C.; Dzobo, K.; Adu, F.; Chopera, D.; Wonkam, A.; Skelton, M.; Blackhurst, D.; Dandara, C. Inhibition of CYP2B6 by medicinal plant extracts: Implication for use of efavirenz and nevirapine-based highly active anti-retroviral therapy (HAART) in resource-limited settings. Molecules 2016, 21, 211. [Google Scholar] [CrossRef] [PubMed]
- Kumar, S.; Rao, P.S.S.; Earla, R.; Kumar, A. Drug-drug interactions between anti-retroviral therapies and drugs of abuse in HIV systems. Expert Opin. Drug Metab. Toxicol. 2015, 11, 343–355. [Google Scholar] [CrossRef] [Green Version]
- Sileo, K.M.; Simbayi, L.C.; Abrams, A.; Cloete, A.; Kiene, S.M. The role of alcohol use in antiretroviral adherence among individuals living with HIV in South Africa: Event-level findings from a daily diary study. Drug Alcohol Depend. 2016, 167, 103–111. [Google Scholar] [CrossRef] [Green Version]
- Magidson, J.F.; Saal, W.; Nel, A.; Remmert, J.E.; Kagee, A. Relationship between depressive symptoms, alcohol use, and antiretroviral therapy adherence among HIV-infected, clinic-attending patients in South Africa. J. Health Psychol. 2017, 22, 1426–1433. [Google Scholar] [CrossRef]
- Peltzer, K.; Friend-du Preez, N.; Ramlagan, S.; Fomundam, H.; Anderson, J. Traditional complementary and alternative medicine and antiretroviral treatment adherence among HIV patients in Kwazulu-Natal, South Africa. Afr. J. Tradit. Complementary Altern. Med. 2009, 7, 125–137. [Google Scholar] [CrossRef] [Green Version]
- Peltzer, K.; Preez, N.F.; Ramlagan, S.; Fomundam, H.; Anderson, J.; Chanetsa, L. Antiretrovirals and the use of traditional, complementary and alternative medicine by HIV patients in Kwazulu-Natal, South Africa: A longitudinal study. Afr. J. Tradit. Complementary Altern. Med. 2011, 8, 337–345. [Google Scholar] [CrossRef] [PubMed]
- Peltzer, K.; Preez, N.; Ramlagan, S.; Fomundam, H. Use of traditional complementary and alternative medicine for HIV patients in KwaZulu-Natal, South Africa. BMC Public Health 2008, 8, 255. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pinillos, F.; Dandara, C.; Swart, M.; Strehlau, R.; Kuhn, L.; Patel, F.; Coovadia, A.; Abrams, E. Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: The role of CYP2B6 genetic variation. BMC Infect. Dis. 2016, 16, 56. [Google Scholar] [CrossRef] [Green Version]
- Müller, T.E.; Ellwanger, J.H.; Michita, R.T.; Matte, M.C.C.; Renner, J.D.P. CYP2B6 516 G > T polymorphism and side effects of the central nervous system in HIV-positive individuals under Efavirenz treatment: Study of a sample from southern Brazil. An. Acad. Bras. Cienc. 2017, 89, 497–504. [Google Scholar] [CrossRef] [Green Version]
- Lamorde, M.; Wang, X.; Neary, M.; Bisdomini, E.; Nakalema, S.; Byakika-Kibwika, P.; Mukonzo, J.K.; Khan, W.; Owen, A.; McClure, M.; et al. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of efavirenz 400 mg once daily during pregnancy and post-partum. Clin. Infect. Dis. 2018, 67, 785–790. [Google Scholar] [CrossRef] [Green Version]
- Group, E.S. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): A randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet 2014, 383, 1474–1482. [Google Scholar] [CrossRef]
- Soeria-Atmadja, S.; Österberg, E.; Gustafsson, L.L.; Dahl, M.-L.; Eriksen, J.; Rubin, J.; Navér, L. Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin. PLoS ONE 2017, 12, e0181316. [Google Scholar] [CrossRef]
- Reay, R.; Dandara, C.; Viljoen, M.; Rheeders, M. CYP2B6 haplotype predicts efavirenz plasma concentration in black South African HIV-1-Infected children: A longitudinal pediatric pharmacogenomic study. Omics 2017, 21, 465–473. [Google Scholar] [CrossRef]
- Dhoro, M.; Zvada, S.; Ngara, B.; Nhachi, C.; Kadzirange, G.; Chonzi, P.; Masimirembwa, C. CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: Population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe. BMC Pharmacol. Toxicol. 2015, 16, 4. [Google Scholar] [CrossRef] [Green Version]
- Ma, J.D.; Lee, K.C.; Kuo, G.M. HLA-B*5701 testing to predict abacavir hypersensitivity. PLoS Curr. 2010, 2, RRN1203. [Google Scholar] [CrossRef] [PubMed]
- Hughes, D.A.; Vilar, F.J.; Ward, C.C.; Alfirevic, A.; Park, B.K.; Pirmohamed, M. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 2004, 14, 335–342. [Google Scholar] [CrossRef] [PubMed]
- Matimba, A.; Dhoro, M.; Dandara, C. Is there a role of pharmacogenomics in Africa. Glob. Health Epidemiol. Genom. 2016, 1, e9. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Abadsidis, S. CDC Officially Admits People with HIV Who Are Undetectable Can’t Transmit HIV. 2017. Available online: https://www.hivplusmag.com/undetectable/2017/9/27/breaking-cdc-officially-recognizes-undetectableuntransmittable-hiv-prevention (accessed on 6 August 2020).
- O’Connor, J.; Smith, C.; Lampe, F.C.; Johnson, M.A.; Chadwick, D.R.; Nelson, M.; Dunn, D.; Winston, A.; Post, F.A.; Sabin, C.; et al. Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: An observational cohort study. Lancet HIV 2017, 4, e295–e302. [Google Scholar] [CrossRef] [Green Version]
- Ngure, K.; Ongolly, F.; Dolla, A.; Awour, M.; Mugwanya, K.K.; Irungu, E.; Mugo, N.; Bukusi, E.A.; Morton, J.; Odoyo, J.; et al. “I just believe there is a risk” understanding of undetectable equals untransmissible (U = U) among health providers and HIV-negative partners in serodiscordant relationships in Kenya. J. Int. AIDS Soc. 2020, 23, e25466. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Musinguzi, N.; Mocello, R.A.; Boum, Y., 2nd; Hunt, P.W.; Martin, J.N.; Haberer, J.E.; Bangsberg, D.R.; Siedner, M.J. Duration of viral suppression and risk of rebound viremia with first-line antiretroviral therapy in rural uganda. AIDS Behav. 2017, 21, 1735–1740. [Google Scholar] [CrossRef] [PubMed]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Thomford, N.E.; Mhandire, D.; Dandara, C.; Kyei, G.B. Promoting Undetectable Equals Untransmittable in Sub-Saharan Africa: Implication for Clinical Practice and ART Adherence. Int. J. Environ. Res. Public Health 2020, 17, 6163. https://doi.org/10.3390/ijerph17176163
Thomford NE, Mhandire D, Dandara C, Kyei GB. Promoting Undetectable Equals Untransmittable in Sub-Saharan Africa: Implication for Clinical Practice and ART Adherence. International Journal of Environmental Research and Public Health. 2020; 17(17):6163. https://doi.org/10.3390/ijerph17176163
Chicago/Turabian StyleThomford, Nicholas Ekow, Doreen Mhandire, Collet Dandara, and George B. Kyei. 2020. "Promoting Undetectable Equals Untransmittable in Sub-Saharan Africa: Implication for Clinical Practice and ART Adherence" International Journal of Environmental Research and Public Health 17, no. 17: 6163. https://doi.org/10.3390/ijerph17176163